Wednesday, February 14, 2018

EyewireTV -- Glaucoma Experts Discuss Future Technologies and Treatment Options

In this week’s EyewireTV, at the annual Glaucoma 360 meeting in San Francisco, experts discuss which technologies and treatments they believe will have a major impact on the way glaucoma patients are treated.

Watch Video

Wednesday, February 07, 2018

EyewireTV -- ReVision Optics Shuts Down; Diabetes-Cataract Incidence Study

In this week’s EyewireTV, ReVision Optics, the maker of the Raindrop Near Vision Inlay, has gone out of business; and a large British study reveals that people with diabetes are twice as likely to develop cataracts as the general population. Also, Second Sight Medical Products provides an update on its products, including the first-in-human implant of the Orion Cortical Visual Prosthesis System.

Watch Video

Wednesday, January 31, 2018

EyewireTV - Study Identifies a Genetic Link to Glaucoma Risk; New Imprimis Formulations

In this week’s EyewireTV, a groundbreaking new study has found a genetic link between thinner corneas and increased risk of glaucoma; and Imprimis Pharmaceuticals says it will be dispensing two new glaucoma formulations: preservative-free dorzolamide and preservative-free dorzolamide/timolol. Also, Novartis announces that it is licensing Spark Therapeutics’ gene therapy voretigene neparvovec for biallelic RPE65 mutation-associated retinal dystrophy in all markets outside the United States.

Watch Video

Wednesday, January 24, 2018

EyewireTV-New Device Images Entire Eye; FDA Clears OCT Platform

In this week’s EyewireTV, researchers in Poland develop the first OCT imaging system that can provide a detailed image of the entire eye; and Topcon Medical Systems receives FDA 510(k) clearance for the DRI OCT Triton Series. Also, Bausch + Lomb receives FDA approval for Lumify (brimonidine tartrate ophthalmic solution .025%) for the treatment of ocular redness.

Watch Video

Wednesday, January 17, 2018

EyewireTV -- FDA Warns Imprimis Over Claims; New ASCRS Leader

In this week’s EyewireTV, the FDA issues a warning letter to Imprimis Pharmaceuticals, claiming the maker of compounded drugs made false or misleading claims about some of its formulations on the company’s website and Twitter account; and Bausch + Lomb receives CE Mark for the Stellaris Elite Vision Enhancement System, the company’s next-generation ophthalmic surgical platform. Also, the American Society of Cataract and Refractive Surgery names veteran industry executive Stephen Speares as its executive director.

Watch Video

Wednesday, January 10, 2018

EyewireTV — Kala and Sun Provide Updates on DED Drug Candidates; Late-Stage AMD Candidate Fails

In this week’s EyewireTV, Kala Pharmaceuticals reports mixed results from two late-stage studies of its potential blockbuster dry eye disease candidate KPI-121 0.25%; and Sun Pharmaceutical submits a new drug application to the FDA for dry eye drug candidate OTX-101 (cyclosporine A, ophthalmic solution 0.09%). Also, Ohr Pharmaceutical suffers a major setback as its late-stage drug candidate for wet AMD fails to reach the primary efficacy endpoint.

Watch Video
Load More